Skip to main content
Top
Published in: Medical Oncology 8/2020

Open Access 01-08-2020 | Original Paper

Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme)

Authors: Elise Deluche, Tiffany Darbas, Kevin Bourcier, Loic Montangon, Geraldine Bayard, Evelyne Caille, Julie Querrioux, Chantal Suchaud, Sonia Zabaleta, Sabine Chaput, Valerie Le Brun-Ly, Julia Pestre, Laurence Venat, Frédéric Thuillier, Elodie Nevado, Gaelle Maillan, Jeremy Jost, Sophie Leobon, Nicole Tubiana-Mathieu, Sandrine Lavau-Denes

Published in: Medical Oncology | Issue 8/2020

Login to get access

Abstract

Oral therapies have highly modified cancer patient management and changed hospital practises. We introduce a specific Oral Therapy Centre and retrospectively review information prospectively recorded by co-ordination nurses (CNs) (the DICTO programme). We describe the roles played by CNs in the management of oral cancer therapies at Limoges Dupuytren Hospital between May 2015 and June 2018. All cancers, irrespective of stage or whether oral general chemotherapy or targeted therapy was prescribed, are included. We followed up 287 patients of median age 67 years (range 26–89 years). Of these, 76% had metastases and 44% were on first-line therapy. The vast majority (88%) of their first CN contacts occurred just after physician consultation and lasted an average of 60 min. As part of follow-up, the CNs made 2719 calls (average 10 min) to patients to educate them and to verify compliance and drug tolerance. They also received 833 calls from patients (70%) or their relatives or health professionals (30%) seeking advice on management of side effects. In addition to the initial appointments, 1069 non-scheduled follow-up visits were made to assess side effects (49.2%). The CNs devoted 5 h to each patient over 3 months of treatment (i.e. 25 min/day) and, also organised scheduled hospitalisations in the department of oncology for 51% of patients. We show the interest and real-life work in a specific oral therapy centre within oncology department with the role of CNs to facilitate the global health care of the patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jacobs JM, Pensak NA, Sporn NJ, MacDonald JJ, Lennes IT, Safren SA, et al. Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. JOP. 2017;13:e474–e485485.CrossRef Jacobs JM, Pensak NA, Sporn NJ, MacDonald JJ, Lennes IT, Safren SA, et al. Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. JOP. 2017;13:e474–e485485.CrossRef
2.
go back to reference Jacobs JM, Ream ME, Pensak N, Nisotel LE, Fishbein JN, MacDonald JJ, et al. Patient experiences with oral chemotherapy: adherence, symptoms, and quality of life. J Natl Compr Cancer Netw. 2019;17:221–8.CrossRef Jacobs JM, Ream ME, Pensak N, Nisotel LE, Fishbein JN, MacDonald JJ, et al. Patient experiences with oral chemotherapy: adherence, symptoms, and quality of life. J Natl Compr Cancer Netw. 2019;17:221–8.CrossRef
3.
go back to reference Palmer DH, Johnson PJ. Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. Cancer Metastasis Rev. 2015;34:497–509.CrossRef Palmer DH, Johnson PJ. Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. Cancer Metastasis Rev. 2015;34:497–509.CrossRef
4.
go back to reference Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.CrossRef Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.CrossRef
5.
go back to reference Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17:239–45.CrossRef Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17:239–45.CrossRef
6.
go back to reference Bassan F, Peter F, Houbre B, Brennstuhl MJ, Costantini M, Speyer E, et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl). 2014;23:22–35.CrossRef Bassan F, Peter F, Houbre B, Brennstuhl MJ, Costantini M, Speyer E, et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl). 2014;23:22–35.CrossRef
7.
go back to reference Holle LM, Puri S, Clement JM. Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice. J Oncol Pharm Pract. 2016;22:511–6.CrossRef Holle LM, Puri S, Clement JM. Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice. J Oncol Pharm Pract. 2016;22:511–6.CrossRef
8.
go back to reference Schneider SM, Hess K, Gosselin T. Interventions to promote adherence with oral agents. Semin Oncol Nurs. 2011;27:133–41.CrossRef Schneider SM, Hess K, Gosselin T. Interventions to promote adherence with oral agents. Semin Oncol Nurs. 2011;27:133–41.CrossRef
9.
go back to reference Bordonaro S, Romano F, Lanteri E, Cappuccio F, Indorato R, Butera A, et al. Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy. Patient Prefer Adherence. 2014;8:917–23.CrossRef Bordonaro S, Romano F, Lanteri E, Cappuccio F, Indorato R, Butera A, et al. Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy. Patient Prefer Adherence. 2014;8:917–23.CrossRef
10.
go back to reference Cnossen IC, van Uden-Kraan CF, Eerenstein SEJ, Jansen F, Witte BI, Lacko M, et al. An online self-care education program to support patients after total laryngectomy: feasibility and satisfaction. Support Care Cancer. 2016;24:1261–8.CrossRef Cnossen IC, van Uden-Kraan CF, Eerenstein SEJ, Jansen F, Witte BI, Lacko M, et al. An online self-care education program to support patients after total laryngectomy: feasibility and satisfaction. Support Care Cancer. 2016;24:1261–8.CrossRef
11.
go back to reference Craven O, Hughes CA, Burton A, Saunders MP, Molassiotis A. Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer. Eur J Cancer Care. 2013;22:413–9.CrossRef Craven O, Hughes CA, Burton A, Saunders MP, Molassiotis A. Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer. Eur J Cancer Care. 2013;22:413–9.CrossRef
12.
go back to reference Gervès-Pinquié C, Daumas-Yatim F, Lalloué B, Girault A, Ferrua M, Fourcade A, et al. Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial. BMC Health Serv Res. 2017;17:133.CrossRef Gervès-Pinquié C, Daumas-Yatim F, Lalloué B, Girault A, Ferrua M, Fourcade A, et al. Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial. BMC Health Serv Res. 2017;17:133.CrossRef
14.
go back to reference Maritaz C, Gault N, Roy C, Tubach F, Burnel S, Lotz J-P. Impact of a coordinated regional organization to secure the management of patients on oral anticancer drugs: CHIMORAL, a comparative trial. Bull Cancer. 2019;106:734–46.CrossRef Maritaz C, Gault N, Roy C, Tubach F, Burnel S, Lotz J-P. Impact of a coordinated regional organization to secure the management of patients on oral anticancer drugs: CHIMORAL, a comparative trial. Bull Cancer. 2019;106:734–46.CrossRef
16.
go back to reference Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, et al. Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS ONE. 2014;9(12):e115060.CrossRef Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, et al. Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS ONE. 2014;9(12):e115060.CrossRef
19.
go back to reference Zerillo JA, Goldenberg BA, Kotecha RR, Tewari AK, Jacobson JO, Krzyzanowska MK. Interventions to improve oral chemotherapy safety and quality: a systematic review. JAMA Oncol. 2018;4:105–17.CrossRef Zerillo JA, Goldenberg BA, Kotecha RR, Tewari AK, Jacobson JO, Krzyzanowska MK. Interventions to improve oral chemotherapy safety and quality: a systematic review. JAMA Oncol. 2018;4:105–17.CrossRef
20.
go back to reference Deppenweiler M, Falkowski S, Saint-Marcoux F, Monchaud C, Picard N, Laroche M-L, et al. Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacol Res. 2017;121:138–44.CrossRef Deppenweiler M, Falkowski S, Saint-Marcoux F, Monchaud C, Picard N, Laroche M-L, et al. Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacol Res. 2017;121:138–44.CrossRef
21.
go back to reference Rougeot J, Nevado E, Maillan G, Marie-Daragon A, Leobon sophie, Tubiana-Mathieu N, et al. 164 PP - Le dispositif de prise en charge des patients traités par thérapie orale au sein d’un service d’oncologie médicale, illustré par la molécule évérolimus. Syndicat National des Pharmaciens Praticiens Hospitaliers et Praticiens Hospitaliers Universitaires; 2016. https://www.snphpu.org/poster.php?HiNum=9535. Rougeot J, Nevado E, Maillan G, Marie-Daragon A, Leobon sophie, Tubiana-Mathieu N, et al. 164 PP - Le dispositif de prise en charge des patients traités par thérapie orale au sein d’un service d’oncologie médicale, illustré par la molécule évérolimus. Syndicat National des Pharmaciens Praticiens Hospitaliers et Praticiens Hospitaliers Universitaires; 2016. https://​www.​snphpu.​org/​poster.​php?​HiNum=​9535.
22.
go back to reference Coolbrandt A, Wildiers H, Aertgeerts B, Van der Elst E, Laenen A, Dierckx de Casterlé B, et al. Characteristics and effectiveness of complex nursing interventions aimed at reducing symptom burden in adult patients treated with chemotherapy: a systematic review of randomized controlled trials. Int J Nurs Stud. 2014;51:495–510.CrossRef Coolbrandt A, Wildiers H, Aertgeerts B, Van der Elst E, Laenen A, Dierckx de Casterlé B, et al. Characteristics and effectiveness of complex nursing interventions aimed at reducing symptom burden in adult patients treated with chemotherapy: a systematic review of randomized controlled trials. Int J Nurs Stud. 2014;51:495–510.CrossRef
23.
go back to reference Poort H, Jacobs JM, Pirl WF, Temel JS, Greer JA. Fatigue in patients on oral targeted or chemotherapy for cancer and associations with anxiety, depression, and quality of life. Palliat Support Care. 2019;18:141–7.CrossRef Poort H, Jacobs JM, Pirl WF, Temel JS, Greer JA. Fatigue in patients on oral targeted or chemotherapy for cancer and associations with anxiety, depression, and quality of life. Palliat Support Care. 2019;18:141–7.CrossRef
24.
go back to reference Yahiro Y, Nakai Y, Higashi A. A literature review of studies examining the psychological aspects of cancer patients receiving outpatients chemotherapy. J Jpn Soc Nurs Res. 2012;35:5. Yahiro Y, Nakai Y, Higashi A. A literature review of studies examining the psychological aspects of cancer patients receiving outpatients chemotherapy. J Jpn Soc Nurs Res. 2012;35:5.
25.
go back to reference Lai XB, Ching SSY, Wong FKY, Leung CWY, Lee LH, Wong JSY, et al. A nurse-led care program for breast cancer patients in a chemotherapy day center: a randomized controlled trial. Cancer Nurs. 2019;42:20–34.CrossRef Lai XB, Ching SSY, Wong FKY, Leung CWY, Lee LH, Wong JSY, et al. A nurse-led care program for breast cancer patients in a chemotherapy day center: a randomized controlled trial. Cancer Nurs. 2019;42:20–34.CrossRef
26.
go back to reference Handa S, Okuyama H, Yamamoto H, Nakamura S, Kato Y. Effectiveness of a smartphone application as a support tool for patients undergoing breast cancer chemotherapy: a randomized controlled trial. Clin Breast Cancer. 2020;20:201.CrossRef Handa S, Okuyama H, Yamamoto H, Nakamura S, Kato Y. Effectiveness of a smartphone application as a support tool for patients undergoing breast cancer chemotherapy: a randomized controlled trial. Clin Breast Cancer. 2020;20:201.CrossRef
27.
go back to reference Lai XB, Ching SSY, Wong FKY, Leung CWY, Lee LH, Wong JSY, et al. The cost-effectiveness of a nurse-led care program for breast cancer patients undergoing outpatient-based chemotherapy—a feasibility trial. Eur J Oncol Nurs. 2018;36:16–25.CrossRef Lai XB, Ching SSY, Wong FKY, Leung CWY, Lee LH, Wong JSY, et al. The cost-effectiveness of a nurse-led care program for breast cancer patients undergoing outpatient-based chemotherapy—a feasibility trial. Eur J Oncol Nurs. 2018;36:16–25.CrossRef
28.
go back to reference Occhipinti S, Petit-Jean E, Pinguet F, Beaupin C, Daouphars M, Parent D, et al. Pharmacist involvement in supporting care in patients receiving oral anticancer therapies: a situation report in French cancer centers. Bull Cancer. 2017;104:727–34.CrossRef Occhipinti S, Petit-Jean E, Pinguet F, Beaupin C, Daouphars M, Parent D, et al. Pharmacist involvement in supporting care in patients receiving oral anticancer therapies: a situation report in French cancer centers. Bull Cancer. 2017;104:727–34.CrossRef
29.
go back to reference O’Bryant CL, Crandell BC. Community pharmacists’ knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc. 2008;48:632–9.CrossRef O’Bryant CL, Crandell BC. Community pharmacists’ knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc. 2008;48:632–9.CrossRef
30.
go back to reference Mekdad SS, AlSayed AD. Towards safety of oral anti-cancer agents, the need to educate our pharmacists. Saudi Pharm J. 2017;25:136–40.CrossRef Mekdad SS, AlSayed AD. Towards safety of oral anti-cancer agents, the need to educate our pharmacists. Saudi Pharm J. 2017;25:136–40.CrossRef
Metadata
Title
Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme)
Authors
Elise Deluche
Tiffany Darbas
Kevin Bourcier
Loic Montangon
Geraldine Bayard
Evelyne Caille
Julie Querrioux
Chantal Suchaud
Sonia Zabaleta
Sabine Chaput
Valerie Le Brun-Ly
Julia Pestre
Laurence Venat
Frédéric Thuillier
Elodie Nevado
Gaelle Maillan
Jeremy Jost
Sophie Leobon
Nicole Tubiana-Mathieu
Sandrine Lavau-Denes
Publication date
01-08-2020
Publisher
Springer US
Published in
Medical Oncology / Issue 8/2020
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-020-01393-7

Other articles of this Issue 8/2020

Medical Oncology 8/2020 Go to the issue